- Home
- STTK vs NMTC Comparison
STTK vs NMTC Comparison
Compare STTK & NMTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- NMTC
- Stock Information
- Founded
- STTK 2016
- NMTC 2009
- Country
- STTK United States
- NMTC United States
- Employees
- STTK N/A
- NMTC N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- NMTC Medical/Dental Instruments
- Sector
- STTK Health Care
- NMTC Health Care
- Exchange
- STTK Nasdaq
- NMTC Nasdaq
- Market Cap
- STTK 37.6M
- NMTC 30.9M
- IPO Year
- STTK 2020
- NMTC N/A
- Fundamental
- Price
- STTK $0.91
- NMTC $0.66
- Analyst Decision
- STTK Hold
- NMTC Strong Buy
- Analyst Count
- STTK 4
- NMTC 1
- Target Price
- STTK $3.00
- NMTC $1.45
- AVG Volume (30 Days)
- STTK 108.4K
- NMTC 390.9K
- Earning Date
- STTK 05-01-2025
- NMTC 05-13-2025
- Dividend Yield
- STTK N/A
- NMTC N/A
- EPS Growth
- STTK N/A
- NMTC N/A
- EPS
- STTK N/A
- NMTC N/A
- Revenue
- STTK $4,606,000.00
- NMTC $5,758,777.00
- Revenue This Year
- STTK N/A
- NMTC $292.88
- Revenue Next Year
- STTK N/A
- NMTC N/A
- P/E Ratio
- STTK N/A
- NMTC N/A
- Revenue Growth
- STTK 69.65
- NMTC 54.53
- 52 Week Low
- STTK $0.69
- NMTC $0.40
- 52 Week High
- STTK $11.76
- NMTC $1.39
- Technical
- Relative Strength Index (RSI)
- STTK 47.64
- NMTC 51.39
- Support Level
- STTK $0.84
- NMTC $0.61
- Resistance Level
- STTK $1.00
- NMTC $0.71
- Average True Range (ATR)
- STTK 0.09
- NMTC 0.05
- MACD
- STTK 0.01
- NMTC 0.02
- Stochastic Oscillator
- STTK 42.02
- NMTC 44.03
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About NMTC NeuroOne Medical Technologies Corporation
NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.